cefixime has been researched along with erythromycin in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.25) | 18.7374 |
| 1990's | 2 (12.50) | 18.2507 |
| 2000's | 7 (43.75) | 29.6817 |
| 2010's | 6 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bingen, E; Bourgeois, F; Chardon, H; Doit, C; Lambert-Zechovsky, N | 1 |
| Flanagan, C; Nash, DR; Steele, LC; Wallace, RJ | 1 |
| Noel, GJ; Teele, DW | 1 |
| Egawa, S; Endo, K; Hosobe, T; Kiyota, H; Kobayashi, I; Onodera, S; Suzuki, H; Takahashi, T | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Arakawa, Y; Kimura, K; Nagano, N; Nagano, Y; Tamai, K; Yanagisawa, H | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Allen, VG; Farrell, DJ; Lo, S; Low, DE; Melano, RG; Perusini, SJ; Rebbapragada, A; Tan, J; Tijet, N; Towns, L | 1 |
| Grime, K; Paine, SW | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for cefixime and erythromycin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
15 other study(ies) available for cefixime and erythromycin
| Article | Year |
|---|---|
Killing kinetics of five orally administered antibiotics at clinically achievable concentrations against Moraxella catarrhalis.
Topics: Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Cefaclor; Cefixime; Cefotaxime; Cefuroxime; Child; Clavulanic Acid; Clavulanic Acids; Colony Count, Microbial; Drug Combinations; Drug Therapy, Combination; Erythromycin; Humans; Microbial Sensitivity Tests; Moraxella catarrhalis | 1992 |
Comparison of the activity of cefixime and activities of other oral antibiotics against adult clinical isolates of Moraxella (Branhamella) catarrhalis containing BRO-1 and BRO-2 and Haemophilus influenzae.
Topics: Administration, Oral; Adult; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; beta-Lactamases; Cefixime; Cefotaxime; Cephalosporins; Clavulanic Acids; Dose-Response Relationship, Drug; Drug Therapy, Combination; Erythromycin; Haemophilus influenzae; Humans; Microbial Sensitivity Tests; Moraxella catarrhalis; Tetracycline | 1991 |
In vitro activities of selected new and long-acting cephalosporins against Pasteurella multocida.
Topics: Cefaclor; Cefixime; Cefoperazone; Cefotaxime; Ceftriaxone; Cephalosporins; Cephalothin; Cloxacillin; Erythromycin; Humans; Microbial Sensitivity Tests; Moxalactam; Oxacillin; Pasteurella; Penicillin G; Penicillin V | 1986 |
Enhancement of antimicrobial activities of cefteram or clavulanic acid/amoxicillin against cefixime-resistant Neisseria gonorrhoeae in the presence of clarithromycin or azithromycin.
Topics: Amoxicillin; Anti-Bacterial Agents; Azithromycin; beta-Lactams; Cefixime; Cefmenoxime; Clarithromycin; Clavulanic Acid; Drug Resistance, Bacterial; Drug Synergism; Erythromycin; Humans; Male; Neisseria gonorrhoeae | 2006 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
Topics: Aminoacyltransferases; Anti-Bacterial Agents; Bacterial Proteins; Female; Genetic Heterogeneity; Humans; Infant, Newborn; Microbial Sensitivity Tests; Molecular Sequence Data; Penicillin Resistance; Penicillin-Binding Proteins; Penicillins; Phylogeny; Sequence Analysis, DNA; Streptococcus agalactiae | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Molecular analysis of antimicrobial resistance mechanisms in Neisseria gonorrhoeae isolates from Ontario, Canada.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; Cefixime; Ceftriaxone; Cephalosporins; DNA, Bacterial; Drug Resistance, Bacterial; Gonorrhea; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Neisseria gonorrhoeae; Ontario; Penicillin-Binding Proteins; Polymerase Chain Reaction; Sequence Analysis, DNA | 2011 |
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Bile; Body Weight; Dogs; Drug Administration Routes; Humans; Liver; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Organic Anion Transporters; Pharmaceutical Preparations; Protein Binding; Rats; Species Specificity | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |